

Article

Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas

Ivonne Vazquez, Natalia Papaleo, Eugenia Garcia, Marta Salido, Antonio Salar, Silvia Hernandez, Xavier Calvo and Luis Colomo

Table S1. CD10 versus MYC gene status according diagnostic categories in 362 cases of LBCL with available results.

| | BL | FL g3A | tDLBCL | DLBCL | HGBL-DH/TH | HGBL, NOS |
|----------------------------------|--------------|--------------|-------------|-----------------|--------------|------------|
| CD10-positive cases (N) * | 28 | 23 | 31 | 83 | 25 | 7 |
| <i>MYC-R</i> | 28/28 (100%) | 0/23 (0%) | 7/31 (23%) | 10/83 (12%) | 25/25 (100%) | 6/7 (86%) |
| <i>MYC non-R</i> | 0/28 (0%) | 23/23 (100%) | 24/31 (77%) | 73/83 (88%) | 0/25 (0%) | 1/7 (14%) |
| CD10-negative cases (N) * | 0 | 3 | 12 | 144 | 5 | 1 |
| <i>MYC-R</i> | | 0/3 (0%) | 4/12 (33%) | 5/144 (3.5%) | 5/5 (100%) | 1/1 (100%) |
| <i>MYC non-R</i> | | 3/3 (100%) | 8/12 (67%) | 139/144 (96.5%) | 0/5 (0%) | 0/1 (0%) |

* ($p < 0.005$); *MYC-R*, *MYC* rearranged; *MYC non-R*, *MYC* non-rearranged.

Table S2. Five year PFS and OS in 112 patients with aggressive LBCL treated with curative intention.

| | 5 year PFS | 5 year OS | | 5 year OS at transformation | |
|---------------------------|------------|-------------|----|-----------------------------|-------------|
| Diagnosis | | | | | |
| FL g3A | NR | | NR | | NR |
| tDLBCL | 19 | | 73 | | 71 |
| DLBCL | 65 | | 70 | | 77 |
| HGBL, NOS | 50 | | 50 | | 50 |
| HGBL-DH/TH | 21 | $p = 0.007$ | 28 | $p = 0.015$ | 29 |
| <i>MYC-rearranged</i> | 25 | | 40 | | 39 |
| <i>MYC non-rearranged</i> | 57 | $p = 0.007$ | 77 | $p = 0.008$ | 79 |
| MYC + | 36 | | 52 | | 45 |
| MYC - | 60 | $p = 0.001$ | 80 | $p = 0.001$ | 80 |
| LMO2 - | 37 | | 49 | | 44 |
| LMO2 + | 59 | $p = 0.047$ | 83 | $p = 0.002$ | 81 |
| | | | | | $p = 0.003$ |

Table S3. Clinicopathological features of patients with *LMO2* and *MYC* mRNA results.

| Case # | Gender, age | Diagnosis | <i>LMO2</i> mRNA | <i>MYC</i> mRNA | <i>MYC:LMO2</i> | <i>MYC</i> status | Follow-up, months |
|---------|-------------|------------|------------------|-----------------|-----------------|-------------------|-------------------|
| #1 F 94 | | HGBL-DH/TH | 0,0001 | 0,1180 | 803,45 | R | DwD, 12 |
| #2 M 54 | | HGBL-DH/TH | 0,0014 | 0,2385 | 165,93 | R | DwD, 1 |
| #3 M82 | | HGBL-DH/TH | 0,0077 | 0,2284 | 29,67 | R | DwD, 8 |
| #4 M 61 | | HGBL-DH/TH | 0,0167 | 0,0423 | 2,53 | R | AneD, 105 |
| #5 M 68 | | tDLBCL | 0,0119 | 0,1119 | 9,39 | R | AneD, 194 |
| #6 F 78 | | tDLBCL | 0,0079 | 0,0508 | 6,41 | R | AneD, 87 |
| #7 M 48 | | tDLBCL | 0,0383 | 0,1265 | 3,30 | A | DwD, 12 |
| #8 M 77 | | DLBCL | 0,0246 | 0,0107 | 0,44 | G | Dned *, 49 |

R, rearranged; A, amplified; G, gained; DwD, dead with disease; AneD, alive with no evidence of disease; * Dned, dead with no evidence of disease (dead of liver disease).



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).